Recent Updates
Recently added Catalysts
PEPG Negative Sentiment Score: 20/100

PepGen Inc. Class Action: Levi & Korsinsky Reminds PepGen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 8, 2025 – PEPG

Key Takeaway: Levi & Korsinsky, LLP has notified investors of PepGen Inc. about a class action securities lawsuit concerning alleged fraud. The lawsuit seeks to recover losses from investors who experienced negative impacts from alleged false statements regarding the company's lead product candidate, PGN-EDO51, between March 2024 and March 2025. Key allegations include claims of the product's ineffectiveness and the dangers associated with the CONNECT2 study, which may affect its FDA approval. Investors have until August 8, 2025, to request to be appointed as lead plaintiff.

Market Sentiment Analysis

CONCERNS & RISKS

  • The class action alleges that the company's lead product candidate, PGN-EDO51, was less effective and safe than presented.
  • Claims indicate the CONNECT2 study was dangerous or deficient for FDA approval.
  • There are concerns that PepGen may halt the CONNECT2 study due to issues raised.
  • Defendants' public statements were deemed materially false and misleading.

Full Press Release Details

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team:
PEPG investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company’s lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51’s clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in PepGen Inc. during the relevant time frame, you have until August 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the class action lawsuit against PepGen Inc. about?

It addresses alleged securities fraud affecting PepGen Inc. investors from March 2024 to March 2025.

What are the main allegations in the PepGen lawsuit?

Defendants reportedly made misleading claims about PGN-EDO51's effectiveness and safety.

How can PepGen investors participate in the lawsuit?

Interested investors must request lead plaintiff status by August 8, 2025.

Are there any costs to join the PepGen lawsuit?

No, class members may be eligible for compensation at no out-of-pocket cost.

Who should investors contact for more information?

Investors can contact Joseph E. Levi, Esq. via email or phone for details.

Last updated: Jul 11, 2025